Oaktree Acquisition Corp. III Life Sciences reported its financial results for the first quarter of 2026, revealing a net income of $1.39 million, a decrease from $1.66 million in the same period last year. The company generated interest income of $1.85 million from cash held in its trust account, which was offset by general and administrative expenses of $456,538. The decline in net income is attributed to a reduction in interest earned on cash held in the trust account, which fell from $2.10 million in Q1 2025 to $1.85 million in Q1 2026.
As of March 31, 2026, Oaktree Acquisition Corp. III reported total assets of $204.83 million, a slight increase from $203.11 million at the end of 2025. The company’s cash balance outside of the trust account was $1.28 million, down from $1.43 million at the end of the previous year. The trust account held $203.41 million, reflecting a modest increase from $201.56 million at the end of 2025. The company’s liabilities also increased, with total current liabilities rising to $1.62 million from $1.30 million, primarily due to higher accounts payable and amounts due to related parties.
In terms of operational metrics, Oaktree Acquisition Corp. III has not yet identified a specific target for its initial business combination, as it remains in the early stages of its operations since its inception in June 2024. The company has 19,199,029 Class A ordinary shares subject to possible redemption, with a redemption value of $10.60 per share as of March 31, 2026. The company’s shareholder deficit increased to $7.23 million from $6.77 million at the end of 2025, primarily due to the accretion of Class A ordinary shares subject to redemption.
Looking ahead, Oaktree Acquisition Corp. III has until October 25, 2026, to complete its initial business combination. The company has indicated that it may need to raise additional capital to fund its operations and pursue acquisition opportunities. Management has expressed concerns regarding its ability to continue as a going concern if it cannot secure additional financing. The company is actively exploring potential business combinations and is focused on managing its cash flow to support its operational needs while navigating the uncertainties in the current economic environment.
About Oaktree Acquisition Corp. III Life Sciences
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.